Adaptimmune receives Nasdaq delisting notice due to low bid price; intends to request hearing

Adaptimmune Therapeutics PLC

Nasdaq determined ADAP's closing bid price was $0.10 or less for 10 consecutive trading days as of Aug 12, 2025.
Company is subject to delisting under Low Priced Stocks Rule unless it requests a hearing; it intends to do so.
Delisting action stayed pending hearing and any extension granted by Nasdaq Hearings Panel; ADSs continue trading.
Company previously had until Oct 27, 2025 to regain $1.00 bid compliance; new rule triggers separate delisting process.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.